To investigate the patient‐perceived reasons for initiation, perceived benefits, side effects experienced and willingness to continue or restart adjuvant treatment with GLP‐1 RA or SGLT2i in patients with T1DM. Here, GLP1R is linked to type 1 diabetes mellitus.